The FDA has approved Valcyte (valganciclovir hydrochloride [prodrug of ganciclovir], from Roche) for the prevention of cytomegalovirus (CMV) disease in pediatric kidney and heart transplant patients ...

Merck & Co’s – known as MSD outside the US and Canada – Prevymis (letermovir) demonstrated non-inferior efficacy and a more favourable safety profile compared to standard of care valganciclovir in a ...

Please provide your email address to receive an email when new articles are posted on . The FDA recently approved a new indication for Prevymis as a prophylaxis to prevent cytomegalovirus disease in ...

Study to evaluate the safety and exploratory efficacy of SYN002 in recipients of human cytomegalovirus (CMV) positive donor kidneys, and to monitor for viral reactivation over the six months following ...

DENVER — The new standard of care, valganciclovir, is inferior to established combination therapy in patients undergoing high-risk orthotopic liver transplantation, a new study suggests. In the ...

Hematopoietic stem cell transplantation (SCT), being performed with an increasing frequency for a variety of both malignant and non-malignant conditions, is associated with the occurrence of many ...

Cytomegalovirus (CMV) is a ubiquitous herpesvirus that persists indefinitely after primary infection, usually in a latent form in various tissues (e.g., kidney, liver, lung). [1] One percent of ...

Prevymis to focus on disease in high-risk adult kidney transplant recipients. Merck & Co. has announced the FDA approval of Prevymis, a treatment for prophylaxis of cytomegalovirus (CMV) disease in ...

For kidney transplant recipients, infection with a virus called cytomegalovirus may lead to devastating complications. New research suggests that extending the period of preventive treatment after ...

RESEARCH TRIANGLE PARK, N.C., March 12, 2013 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that the ...

Prevymis, a non-nucleoside CMV inhibitor (3,4 dihydro-quinazoline), inhibits viral replication through targeting the viral terminase complex. Merck announced that the Food and Drug Administration (FDA ...